Arava Label Strengthened Following Reports Of Interstitial Lung Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis adds stronger warnings for the rheumatoid arthritis drug following post-marketing reports of interstitial lung disease in Japan. Patients should notify their physician and may need to discontinue therapy if pulmonary symptoms develop. Updated labeling also includes geriatric use information.
You may also be interested in...
First-Time Generics Of Sanofi-Aventis’ Arava Enter Market
FDA appears to have denied Sanofi’s March citizen petition requesting refusal to approve ANDAs without certain bioequivalence studies.
First-Time Generics Of Sanofi-Aventis’ Arava Enter Market
FDA appears to have denied Sanofi’s March citizen petition requesting refusal to approve ANDAs without certain bioequivalence studies.
Arava “Authorized” Generic Will Be Distributed By Prasco
Sanofi-Aventis will supply leflunomide to Prasco, which will distribute the rheumatoid arthritis therapy when other Arava generics enter the market.